NFE2L2 and neoplasm: However, NFE2L2 gene alterations in the primary tumor, both in homo- and in heterozygosity, impact not only on tumor progression, but also on the clinical outcome and in the response to therapy, with patients developing chronic kidney disease after partial nephrectomy [25] and reduced response of metastasis to vascular endothelial growth factor-targeting therapy [26].